Soaring 400% injection!

A few days ago, the CDE official website showed that the neostigmine methyl sulfate injection of Chengdu Yuandong Biopharmaceutical was accepted as a 3-type imitation
.
According to the data from Minet.
com, in 2020, the sales of neostigmine injection, a terminal of public medical institutions in China, exceeded 300 million yuan, a year-on-year increase of more than 400%
.
At present, this product has not been reviewed by any company
.
Data show that neostigmine methyl sulfate injection is used to reverse the effects of postoperative non-depolarizing neuromuscular blocking agents
.
Sales of Neostigmine Injections in China's Public Medical Institutions in Recent Years (Unit: 100 million yuan) Source: China's Public Medical Institutions' Terminal Competitive Landscape According to data from Minet.
com, in recent years, China's urban public hospitals, county-level public hospitals, urban community centers and township health In 2020, the sales of neostigmine injections in the hospital (referred to as Chinese public medical institutions) have grown rapidly, exceeding 300 million yuan in 2020, a year-on-year increase of more than 400%
.
Neostigmine injection mainly includes neostigmine methylsulfate injection and neostigmine methylsulfate injection.
Among them, the production enterprises of neostigmine methylsulfate injection are Shanghai Xinyi Jinzhu Pharmaceutical Co.
, Ltd.
and Jiangsu Pujin Pharmaceutical Co.
, Ltd.
Waiting for 4, but no company has reviewed it yet
.
Prior to this, only the supplementary application for consistency evaluation of Shanghai Xinyi Jinzhu Pharmaceutical was under review and approval.
Guangzhou Ruier Medicine | Hebei Kaiwei Pharmaceutical, Chengdu Xinjie High-tech | Taiji Group Sichuan Taiji Pharmaceutical reported as generic 3 categories.
The product is in the review and approval process, and it will be regarded as a review after approval
.
Source: MED2.
0 China Drug Evaluation Database of Minet.
In 2021, a total of 5 products of Yuandong have been approved for marketing, all of which are reported as imitations of Category 4, which are regarded as over-evaluation
.
It covers antithrombotic drugs, systemic antiviral drugs, diabetes drugs and other therapeutic fields (subcategories), among which, repaglinide metformin tablets (II) and repaglinide metformin tablets (I) are the second domestic companies
.
Source: CDE official website, Minet database